Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer
Verastem Oncology reported positive updated data from the Phase 1b/2a RAMP 205 trial evaluating avutometinib plus defactinib combined with chemotherapy in first-line metastatic pancreatic cancer. The combination achieved an 86% 6-month overall survival rate and a 52% confirmed objective response rate in a cohort of 29 patients, with safety profiles consistent with prior reports.
Key figures
- Drug Name
- avutometinib plus defactinib
- Phase Of Trial
- Phase 1b/2a
- Orr
- 52%
- Pancan award usd
- 3800000
- Six month os rate
- 86%
- Six month pfs rate
- 68%
- Patients rpd2 cohort
- 29
- Metastatic disease pct
- 90%
- Median follow up months
- 9.8
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.